%20(1)%20(1).png)
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes
.png)
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials Johannes F E Mann, Thomas Hansen, Thomas Idorn, Lawrence A Leiter, Steven P Marso, Peter Rossing, Jochen Seufert, Sayeh Tadayon, Tina Vilsbøll
Summary
Background Patients with type 2 diabetes have a high risk of developing chronic kidney disease. We examined the effects of semaglutide on kidney function and safety in a large, broad type 2 diabetes population.
Methods We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1–5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial, to examine the effects of once-weekly subcutaneous semaglutide 0·5 mg and 1·0 mg versus comparators (active treatments or placebo) on estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), and kidney adverse events. Data from SUSTAIN 1–5 and SUSTAIN 7 were pooled. eGFR and UACR were also analysed by kidney function and albuminuria status.
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials Johannes F E Mann, Thomas Hansen, Thomas Idorn, Lawrence A Leiter, Steven P Marso, Peter Rossing, Jochen Seufert, Sayeh Tadayon, Tina Vilsbøll
Summary
Background Patients with type 2 diabetes have a high risk of developing chronic kidney disease. We examined the effects of semaglutide on kidney function and safety in a large, broad type 2 diabetes population.
Methods We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1–5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial, to examine the effects of once-weekly subcutaneous semaglutide 0·5 mg and 1·0 mg versus comparators (active treatments or placebo) on estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), and kidney adverse events. Data from SUSTAIN 1–5 and SUSTAIN 7 were pooled. eGFR and UACR were also analysed by kidney function and albuminuria status.
.png "Hướng dẫn download ti liệu")
%20(1).png "Hướng dẫn download ti liệu")
%20(1).png "Gói VIP Member EBOOKBKMT - Hỗ trợ tài liệu nhanh nhất, ưu tiên cho thành viên VIP (Update 2026)")
.png "SÁCH - Cẩm nang thợ điện học - Từ phổ thông tới thợ điện (Nguyễn Văn Phong) Full")
.png "QUYẾT ĐỊNH 438:QĐ-CT - Ban hành Quy chế giáo dục chính trị trong Quân đội nhân dân và Dân quân tự vệ Việt Nam (Full)")
%20(1).png "SÁCH - Tính toán và thiết kế hệ thống sấy (Trần Văn Phú) Full")
.png "SÁCH - Cơ sở thiết kế máy & chi tiết máy (Trịnh Chất) Full")
Không có nhận xét nào: